Abstract
The occurrence and development of colon cancer is closely related to inflammation. Therefore, this study was conducted a current retrospective research to study the effect of IL-35 (interleukin 35), a newly identified anti-infective factor, on colon cancer development. The expression of IL-35 in colon cancer samples and their adjacent normal mucosa by real-time PCR, ELISA (enzyme-linked immunosorbent assay). The effect of IL-35 on patient survival, colon cancer progression, and its effect on Wnt/β-catenine signaling pathway was also assessed. IL-35 is minimally expressed in colon cancer tissues but is highly expressed in adjacent normal tissues. The down-regulation of IL-35 was significantly associated with the American Cancer Joint Committee stage and overall survival of colon cancer patients. The overexpression of IL-35 in colon cancer cells inhibits cell migration, invasion, proliferation, colony formation and cancer stem cells by inhibiting beta-catenin. IL-35 inhibits colon neoplasms in mouse. Our results suggest that IL-35 has an inhibitory effect on the development of colon cancer as a novel prognostic indicator and potential therapeutic target.
Highlights
Colon cancer is a common malignant tumor of the digestive tract system, of which the incidence is high people of age from 45 to 51 years
The purpose of this study is to analyze the relationship between the level of IL-35 in patients with colon cancer and the correlation between clinical factors, identify the correlation between IL35 expression and survival rate, explore the changes of biological characteristics of colon cancer cells transfected with IL-35 gene, and provide a theoretical basis for evaluating the feasibility of preparing autologous tumor vaccine for the future colon cancer gene immunotherapy
A total of 1720 lymph nodes were removed from 141 patients, of which 403 were metastatic lymph nodes with a total metastasis rate of 23.4%
Summary
Colon cancer is a common malignant tumor of the digestive tract system, of which the incidence is high people of age from 45 to 51 years. During the past two decades in China, especially in large cities, the incidence rate has been increasing significantly, and colon cancer is higher than the trend of rectal cancer. In the United States, there are about 15 million people who get colon cancer each year, representing 15% of all patients diagnosed with cancer, without gender difference [1]. Since 1993, Cohen reported that the five-year survival rate of colon cancer was 54%. The treatment continues to improve, the 5-year survival rate has not improved significantly [2]. Due to the rapid progress of molecular biology theory and technology, monumental strides forward have been achieved in the field of biomedicine, and the research results have been applied to the field of clinical treatment [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
